Back to top

Analyst Blog

Dako, an Agilent Technologies (A - Analyst Report) subsidiary, has entered into an agreement with Eli Lilly and Co. (LLY - Analyst Report) for developing companion diagnostic tests that could help detect people more susceptible to cancer. Eli Lilly is developing a medicine for these prospects.

Agilent had acquired the Danish cancer diagnostics company, Dako, for $2.2 billion (on a debt-free basis) last year. Dako provides antibodies, scientific instruments and software mainly to cancer-related diagnostic labs and collaborates with drug companies for the development of methods to identify patients likely to benefit from certain therapies.

Currently, the healthcare sector is witnessing a revolution and companion diagnostic or personalized medicine is taking the center stage in diagnostics. It has been found that not all treatments are same for cancer patients or any other patients, as some require tests that are more specialized.

Dako’s expertise in the development of methods to identify patients likely to benefit from certain therapies will help Eli Lilly to select patients that may benefit from its ongoing investigational oncology medicine; thus enhancing the diagnostic process.

The whole process may revolutionize the healthcare system, as personalized medicine may become helpful in improving patient care and reducing medical bills. If the companion diagnostic tests really kick off, it would be a positive for the testing companies, with a corresponding positive impact on revenues.

According to Global Industry Analysts, companion diagnostics market may reach $280.2 million by 2017 worldwide. The growth is driven by the enhancement of the drug’s clinical usage, thus reducing the overall cost and risk involved in drug development.

The success of the collaboration may help Agilent to build a position for itself in personalized medical care, a segment that is seeing good growth.

Agilent’s revenue in the third quarter was flat sequentially and up 1.9% year over year, short of management’s expectations of a 2-3% sequential increase ($1.77 billion to $1.79 billion). The newly added Diagnostics and Genomics segment accounted for 9.0% of revenue in the last quarter, up 47.2% sequentially.

Currently, Agilent Technologies has a Zacks Rank #5 (Strong Sell), and Eli Lilly carries a Zacks Rank #2 (Buy) rating.

Please login to or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research


Are you a new Zacks Member or a visitor to

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
ERBA DIAGNO… ERB 3.80 +7.04%
BANCO DO BR… BDORY 14.74 +5.66%
AIR INDUSTR… AIRI 9.99 +4.15%
EQT MIDSTRE… EQM 98.14 +3.38%
WEATHERFORD… WFT 23.64 +3.10%